Literature DB >> 32473311

Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities.

Juan M Saavedra1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32473311      PMCID: PMC7253987          DOI: 10.1016/j.phrs.2020.104958

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


× No keyword cloud information.
  6 in total

1.  Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.

Authors:  Guang Yang; Zihu Tan; Ling Zhou; Min Yang; Lang Peng; Jinjin Liu; Jingling Cai; Ru Yang; Junyan Han; Yafei Huang; Shaobin He
Journal:  Hypertension       Date:  2020-04-29       Impact factor: 10.190

2.  Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?

Authors:  Ying Huang; Changming Xie; Xiaoke Chen; Qianhui Hong; Hui Huang
Journal:  Pharmacol Res       Date:  2020-06-04       Impact factor: 7.658

3.  COVID-19, Angiotensin Receptor Blockers, and the Brain.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2020-05-08       Impact factor: 5.046

4.  ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis.

Authors:  Xue Zhang; Jiong Yu; Li-Ya Pan; Hai-Yin Jiang
Journal:  Pharmacol Res       Date:  2020-05-15       Impact factor: 7.658

5.  Angiotensin receptor blockers and COVID-19.

Authors:  Juan M Saavedra
Journal:  Pharmacol Res       Date:  2020-04-15       Impact factor: 7.658

6.  Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.

Authors:  Francisco J de Abajo; Sara Rodríguez-Martín; Victoria Lerma; Gina Mejía-Abril; Mónica Aguilar; Amelia García-Luque; Leonor Laredo; Olga Laosa; Gustavo A Centeno-Soto; Maria Ángeles Gálvez; Miguel Puerro; Esperanza González-Rojano; Laura Pedraza; Itziar de Pablo; Francisco Abad-Santos; Leocadio Rodríguez-Mañas; Miguel Gil; Aurelio Tobías; Antonio Rodríguez-Miguel; Diego Rodríguez-Puyol
Journal:  Lancet       Date:  2020-05-14       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.